WO2006096800A8 - Immunogenic t cell targets in autoimmune hepatitis and methods of use - Google Patents

Immunogenic t cell targets in autoimmune hepatitis and methods of use

Info

Publication number
WO2006096800A8
WO2006096800A8 PCT/US2006/008346 US2006008346W WO2006096800A8 WO 2006096800 A8 WO2006096800 A8 WO 2006096800A8 US 2006008346 W US2006008346 W US 2006008346W WO 2006096800 A8 WO2006096800 A8 WO 2006096800A8
Authority
WO
WIPO (PCT)
Prior art keywords
methods
autoimmune hepatitis
immunogenic
aih
cell targets
Prior art date
Application number
PCT/US2006/008346
Other languages
French (fr)
Other versions
WO2006096800A2 (en
WO2006096800A3 (en
Inventor
Barbara Rehermann
Heiko Mix
Ansgar W Lohse
Christina Weiler-Normann
Original Assignee
Us Gov Health & Human Serv
Barbara Rehermann
Heiko Mix
Ansgar W Lohse
Christina Weiler-Normann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv, Barbara Rehermann, Heiko Mix, Ansgar W Lohse, Christina Weiler-Normann filed Critical Us Gov Health & Human Serv
Publication of WO2006096800A2 publication Critical patent/WO2006096800A2/en
Publication of WO2006096800A3 publication Critical patent/WO2006096800A3/en
Publication of WO2006096800A8 publication Critical patent/WO2006096800A8/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present disclosure takes advantage of the discovery of several T cell epitopes involved in autoimmune hepatitis (AIH). This discovery makes possible new methods of diagnosing and monitoring the progression or response to therapy of a subject with AIH, as well as kits for diagnosing and monitoring the disease, and methods of treating AIH.
PCT/US2006/008346 2005-03-07 2006-03-06 Immunogenic t cell targets in autoimmune hepatitis and methods of use WO2006096800A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65951305P 2005-03-07 2005-03-07
US60/659,513 2005-03-07

Publications (3)

Publication Number Publication Date
WO2006096800A2 WO2006096800A2 (en) 2006-09-14
WO2006096800A3 WO2006096800A3 (en) 2007-03-22
WO2006096800A8 true WO2006096800A8 (en) 2007-07-12

Family

ID=36888988

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/008346 WO2006096800A2 (en) 2005-03-07 2006-03-06 Immunogenic t cell targets in autoimmune hepatitis and methods of use

Country Status (1)

Country Link
WO (1) WO2006096800A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101921323B (en) * 2009-06-11 2013-04-17 北京华大蛋白质研发中心有限公司 Human protein (ribosomal protein S20) and use thereof in diagnosis of autoimmune hepatitis
FR3096465B1 (en) * 2019-05-22 2024-03-15 Univ Nantes USE OF PD-1 AND CD38 PROTEINS AS MARKERS OF AN ACTIVE AUTOIMMUNE PATHOLOGY

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19805815C1 (en) * 1998-02-13 1999-11-11 Ansgar W Lohse Diagnostic for the detection of autoimmune hepatitis
DE10207135A1 (en) * 2002-02-20 2003-09-11 Euroimmun Gmbh Detection of specific antibodies useful e.g. for diagnosis of autoimmune hepatitis, comprises using pre-adsorbed test sample and recombinant antigen-expressing cell

Also Published As

Publication number Publication date
WO2006096800A2 (en) 2006-09-14
WO2006096800A3 (en) 2007-03-22

Similar Documents

Publication Publication Date Title
WO2007047408A3 (en) Promac signature application
WO2006089091A3 (en) Methods for detecting minimum residual disease
WO2007119111A3 (en) Tissue diagnostics for ovarian cancer
WO2007062090A8 (en) Methods and compositions related to b cell assays
WO2004011611A3 (en) Taci antibodies and uses thereof
WO2005104706A3 (en) Stirred-tank reactor system
WO2006138275A3 (en) Compositions and methods for treating and diagnosing cancer
WO2005113831A3 (en) Biomarkers for multiple sclerosis and methods of use thereof
WO2008084410A3 (en) Human cytomegalovirus neutralising antibodies and use thereof
WO2006090750A8 (en) ANTI-IgSF4 ANTIBODY AND UTILIZATION OF THE SAME
WO2005087951A3 (en) Reagents, methods and kits for use in deactivating nucleic acids
WO2004087758A3 (en) Il 13 receptor alpha 2 antibody and methods of use
SG158133A1 (en) Method for reversing multiple resistance in animal cells
WO2006031986A3 (en) Methods and compositions for diagnosing neoplastic disease
IL179884A0 (en) Fuel cells, micro-fuel cells and methods for the production thereof
WO2007022511A3 (en) Listeria-induced immunorecruitment and activation, and methods of use thereof
WO2010115745A3 (en) Biomarkers, methods and kits for the diagnosis of rheumatoid arthritis
WO2009029971A8 (en) Method for diagnosing the metabolic syndrome (ms)
WO2011074802A3 (en) Kit for diagnosing prostate cancer and diagnosis method
TR201907879T4 (en) Armed vehicle with improved structure.
WO2010032899A3 (en) Eno1-specific human antibody
WO2006091861A8 (en) Compositions and methods relating to cns lymphoma
WO2006135893A3 (en) Methods for diagnosing and treating cerebrovascular events based on nr2 peptides
WO2005034737A3 (en) Methods for diagnosing and treating endoplasmic reticulum (er) stress diseases
WO2006096800A3 (en) Immunogenic t cell targets in autoimmune hepatitis and methods of use

Legal Events

Date Code Title Description
NENP Non-entry into the national phase in:

Ref country code: DE

NENP Non-entry into the national phase in:

Ref country code: RU

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06748320

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06748320

Country of ref document: EP

Kind code of ref document: A2